|Articles|January 1, 2004

Pharmaceutical Executive

Pharmaceutical Executive-01-01-2004

Table of Contents

Table of Contents

External Link - article-80918.pdf

Articles in this issue

over 22 years ago

Article

PE's Annual Sales and Marketing Employment Survey: The Big Squeeze

over 22 years ago

Article

Streamlining For Success with Fred Price of BioMarin

over 22 years ago

Article

The Making of a New Disease

Newsletter

Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.

Related Content

Pharmaceutical Executive Daily

Pharmaceutical Executive Daily: DualityBio and Teva Strike Major Biopharma Deals

ByNicholas Jacobus

August 28th 2026

stock.adobe.com fda approval

FDA Approves Lisraya for Adults with Dermatomyositis, Bixlenvo for Virologically Suppressed Adults with HIV, Mounjaro to Reduce MACE in Adults with Type 2 Diabetes

ByNicholas Jacobus

August 28th 2026

stock.adobe.com business deal

M&A Roundup: DualityBio & Genentech Enter Partnership to Develop Next Generation ADC’s, Teva Bids to Acquire Igalmi from BioXcel

ByNicholas Jacobus

August 28th 2026

Israel Ortiz

Preventing Batch Loss: The Growing Role of Preventive and Predictive Maintenance

August 28th 2026

Parth Khanna

How AI is Being Implemented Alongside Compliance Concerns

ByMike Hollan,Parth Khanna

August 28th 2026

Trending on PharmExec

Trump Administration Preparing New Round of Medicaid Drug-Pricing Deals: Report

Study Shows Link Between Zepbound and Lower Healthcare Costs in Adults Aged 55 and Up with Obesity: Report

Pharmaceutical Executive Daily: DualityBio and Teva Strike Major Biopharma Deals

M&A Roundup: DualityBio & Genentech Enter Partnership to Develop Next Generation ADC’s, Teva Bids to Acquire Igalmi from BioXcel

Moving Beyond the Sample Size Guess: Lessons from 60 Million Clinical Trial Simulations